Web-Based Advance Care Planning for Patients With Advanced Cancer
A Web-Based Advance Care Planning Intervention to Reduce Preferences for Aggressive Life-Sustaining Treatments in Patients With Advanced Cancer: A Randomized Controlled Trial
The goal of this clinical trial is to determine whether a web-based advance care planning (ACP) intervention can reduce preferences for aggressive life-sustaining treatments among patients with advanced cancer.
The main questions it aims to answer are:
- Does a web-based ACP intervention reduce preferences for aggressive life-sustaining treatments among patients with advanced cancer?
- Does a web-based ACP intervention support informed medical decision-making regarding future care?
Researchers will compare a web-based ACP intervention plus a Patient Right to Autonomy Act leaflet with a Patient Right to Autonomy Act leaflet alone to determine whether the web-based ACP intervention is more effective in reducing preferences for aggressive life-sustaining treatments.
Participants will:
- Be randomly assigned to either an intervention group or a control group
- Receive either a web-based ACP educational program plus a Patient Right to Autonomy Act leaflet, or a Patient Right to Autonomy Act leaflet alone
- Complete questionnaires at baseline, immediately after the intervention, and one week after the intervention
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Advance care planning (ACP) is a process that enables individuals to understand and communicate their values, goals, and preferences regarding future medical care. ACP is particularly important for patients with advanced cancer, who may face complex decisions regarding life-sustaining treatments and end-of-life care. However, ACP participation remains limited, and innovative approaches are needed to improve patient engagement.
This study was designed to evaluate the effectiveness of a web-based ACP intervention in reducing preferences for aggressive life-sustaining treatments among patients with advanced cancer. The intervention was developed to provide accessible ACP education and information regarding the Patient Right to Autonomy Act in Taiwan.
A single-blind randomized controlled trial design was used. A total of 110 patients with stage III or IV cancer were recruited and randomly assigned to either an intervention group (n = 55) or a control group (n = 55). Participants in the intervention group received a web-based ACP educational program in addition to a Patient Right to Autonomy Act leaflet, whereas participants in the control group received the leaflet alone.
Outcome assessments were conducted at baseline (T1), immediately after the intervention (T2), and one week after the intervention (T3). The primary objective was to determine whether the web-based ACP intervention reduced preferences for aggressive life-sustaining treatments. The study also examined factors associated with treatment preferences and medical decision-making.
The findings of this study may contribute to the development of accessible ACP interventions and support informed decision-making among patients with advanced cancer.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Taipei City
-
Taipei, Taipei City, Taiwan
- Tri-Service General Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Diagnosed with advanced cancer (stage III or IV)
- Aged 18 years or older
- Able to communicate fluently in Mandarin Chinese or Taiwanese
- Able and willing to provide informed consent
- No cognitive impairment
- Have access to Internet-connected electronic devices at home
- Have not previously received advance care planning (ACP) consultation
- Have not completed an advance directive (AD)
Exclusion Criteria:
- No access to Internet-connected electronic devices at home
- Unable to operate Internet-based electronic devices
- Previous participation in ACP consultation or completion of an AD
- Cognitive impairment
- Severe physical or psychological symptoms that would interfere with participation in the study
- Concurrent participation in another intervention study
- Refusal to participate
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Web-Based ACP Intervention Group
Participants received a web-based advance care planning (ACP) educational program in addition to a Patient Right to Autonomy Act leaflet.
|
A web-based educational program designed to improve advance care planning knowledge, promote informed decision-making, and facilitate discussions regarding future medical care among patients with advanced cancer.
An educational leaflet providing information about the Patient Right to Autonomy Act and advance care planning.
|
|
Sonstiges: Control Group
Participants received a Patient Right to Autonomy Act leaflet only.
|
An educational leaflet providing information about the Patient Right to Autonomy Act and advance care planning.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in Preference for Aggressive Life-Sustaining Treatments
Zeitfenster: Baseline and 1 Week After Intervention
|
Preferences for aggressive life-sustaining treatments were assessed using the Life-Sustaining Treatment Preference Questionnaire.
Higher scores indicate stronger preferences for aggressive life-sustaining treatments.
Changes from baseline were compared between the intervention and control groups.
|
Baseline and 1 Week After Intervention
|
Mitarbeiter und Ermittler
Ermittler
- Studienleiter: Hsueh-Hsing Pan, PhD, National Defense Medical University
- Hauptermittler: Yu-Shiue Lin, National Defense Medical University
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- TSGHIRB No. A202305148
- TSGH_E_113274 (Andere Zuschuss-/Finanzierungsnummer: Tri-Service General Hospital)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Fortgeschrittener Krebs
-
Qilu Pharmaceutical Co., Ltd.Noch keine RekrutierungCLDN18.2-positives Advanced Gallentraktkrebs
-
National University of SingaporeCalifornia Table Grape CommissionRekrutierungAltern | Makula; Degeneration | Advanced Glycation End-ProdukteSingapur
-
Beni-Suef UniversityAktiv, nicht rekrutierendVergleich von Advanced Platelet-Rich Fibrin mit Platelet-Rich Fibrin als Füllmaterial für DefekteÄgypten
-
Extremity MedicalRekrutierungArthrose | Entzündliche Arthritis | Karpaltunnelsyndrom (CTS) | Posttraumatische Arthritis | Scapholunate Advanced Collapse (SLAC) | Scapholunate Crystalline Advanced Collapse (SCAC) | Scaphoid, Trapezium und Trapezoid Advanced Collapse (STTAC) | Kienbock-Krankheit des Erwachsenen | Radiale Malunion | Ulnare Translokation und andere BedingungenVereinigte Staaten
-
Northwell HealthZurückgezogenDiabetes | SGLT-2-Inhibitoren | Advanced Glycation End-Produkte
-
Yongxu JiaAktiv, nicht rekrutierendAdvanced Magen- oder Gastroösophageales Junction (G/GEJ) AdenokarzinomChina
-
Yonsei UniversityNoch keine RekrutierungRAS/BRAF Wildtyp Advanced ColorektalkrebspatientenKorea, Republik von
-
Töölö HospitalTurku University Hospital; Tampere University Hospital; Jyväskylä Central Hospital und andere MitarbeiterRekrutierungArthrose am Handgelenk | Scapholunate Advanced CollapseFinnland
-
University of AlbertaArthritis Society Canada; Wrist Evaluation Canada (WECAN)RekrutierungArthritis | Gelenkerkrankungen | Erkrankungen des Bewegungsapparates | Posttraumatisch; Arthrose | Arthrose am Handgelenk | Kahnbein-Pseudarthrose | Scapholunate Advanced Collapse | Arthropathie am HandgelenkKanada
-
Advanced BionicsAbgeschlossenSchwerer bis hochgradiger Hörverlust | bei erwachsenen Benutzern des Advanced Bionics HiResolution™ Bionic Ear SystemVereinigte Staaten